Ongoing Clinical Trials for Extra-osseous Ewing’s Sarcoma Recurrent

There is currently 1 ongoing clinical trial for patients with extra-osseous Ewing’s sarcoma that has come back after treatment or did not respond to initial therapy. This trial is testing different combinations of chemotherapy medications to find the most effective treatment options. The study is being conducted across multiple European countries including Finland, Denmark, Italy, France, Spain, Austria, Norway, Netherlands, Belgium, and Czechia.

Clinical trial locations

• Austria
  • Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma
• Belgium
  • Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma
• Czechia
  • Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma
• Denmark
  • Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma
• Finland
  • Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma
• France
  • Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma
• Italy
  • Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma
• Netherlands
  • Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma
• Norway
  • Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma
• Spain
  • Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

This study is designed for patients whose Ewing’s sarcoma has either returned after previous treatment or did not respond to initial therapy. The trial tests several different combinations of chemotherapy medications to determine which approach works best.

Main inclusion criteria:

• Patients must be at least 2 years old
• Diagnosis of Ewing sarcoma or Ewing-like sarcoma must be confirmed through tissue examination
• There must be evidence that the disease has progressed during or after completing treatment
• Patients must be physically fit enough to receive the trial treatments
• Kidney function must be adequate, with a specific measure (GFR) of 60 ml/min/1.73m2 or higher
• Imaging tests must be completed within 4 weeks before starting the trial
• Female patients who can become pregnant must have a negative pregnancy test
• Patients must agree to use effective birth control during treatment and for 12 months afterward
• Patients must be eligible for at least two of the treatment options being studied

Main exclusion criteria:

• Patients younger than 6 years or older than 65 years
• Patients whose cancer has not recurred or who have not shown resistance to initial treatment
• Patients who cannot undergo chemotherapy that affects the entire body
• Patients unable to complete the required imaging tests
• Patients with severe medical conditions that would make participation unsafe
• Patients who are pregnant or breastfeeding
• Patients with known allergies to the study medications
• Patients unable to comply with study requirements or attend follow-up visits
• Patients currently participating in other clinical trials that might interfere with this study

Focus and goal:

The main purpose of this trial is to compare different chemotherapy combinations to find out which works best for patients with recurrent or treatment-resistant Ewing’s sarcoma. Researchers want to understand both the effectiveness of each treatment combination and the side effects patients experience. The study will measure how long patients live without their disease getting worse, overall survival time, and quality of life during treatment.

Patients are randomly assigned to one of several treatment groups, each receiving different medication combinations. Some medications are given through a vein (intravenous infusion), while others are taken as pills by mouth. Treatment cycles typically last several weeks, and the total treatment duration may continue for up to 104 weeks, depending on how well it works for each patient.

Throughout the study, doctors carefully monitor tumor size using imaging scans performed after 2, 4, and sometimes 6 cycles of treatment. A special type of scan called PET-CT is done after 4 cycles. Regular monitoring also includes checking blood pressure, liver function, kidney function, and heart function. Doctors track any side effects and record how long patients need to stay in the hospital.

Investigational drugs:

The trial tests several chemotherapy medications including gemcitabine, docetaxel, irinotecan, temozolomide, topotecan, carboplatin, cyclophosphamide, ifosfamide, etoposide, and lenvatinib. These medications are used in different combinations to find the most effective treatment approach. Some are given daily while others are administered on specific days during each treatment cycle.

Summary

Currently, there is one active clinical trial available for patients with extra-osseous Ewing’s sarcoma that has recurred or not responded to initial treatment. This international study is being conducted across 10 European countries, demonstrating strong collaborative research efforts in this rare disease. The trial takes a comprehensive approach by testing multiple chemotherapy combinations to identify the most effective treatment options with manageable side effects. The study accepts patients from age 2 onwards, though specific age restrictions apply depending on certain treatment groups. Patients interested in participating should note that kidney function, heart function, and overall physical fitness are important factors for eligibility, and female patients of childbearing age must use effective contraception during and after treatment.